Author + information
- Yoshikazu Nakaoka,
- Kaori Higuchi,
- Yoh Arita,
- Takahiro Kataoka,
- Taku Yasui,
- Kuniyasu Ikeoka,
- Tomohito Ohtani,
- Yasushi Sakata,
- Keiko Yamauchi–Takihara and
- Issei Komuro
Treatment of refractory Takayasu arteritis (TA) remains a challenging clinical issue. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose. Additionally, GCs therapy is accompanied with a variety of adverse events. The aim of this study was to assess the efficacy and safety of the interleukin–6 (IL–6) receptor (IL–6R) antibody tocilizumab (TCZ) in the patients with refractory TA.
Four patients with TA who had shown GC resistance received TCZ infusions (8mg/kg body weight) every four weeks for at least 18 times (range from 18 to 55). Clinical symptoms of disease activity, the levels of acute phase proteins such as C–reactive protein and serum amyloid A, and GC dosage necessary to maintain remission were prospectively assessed. CT and MRI scan were performed to monitor local inflammation.
The mean duration of TCZ treatment was 22.2 times (range 18–55 times). All patients achieved a rapid normalization of the acute phase proteins and complete clinical response. Remarkably, predonisolone dosage could be reduced to a mean of 2.2mg/day (range 0–3 mg/day). All of the three patients who received TCZ for more than 2 years showed significant reduction in the thickened artery lesions. No relapse and no drug–related side effects were noted in all patients.
In this small group of patients with refractory TA, treatment with TCZ was effective and well–tolerated. Further larger studies are required to confirm our findings.
Poster Sessions, Expo North
Saturday, March 09, 2013, 10:00 a.m.–10:45 a.m.
Session Title: Atherosclerosis, Inflammation, Biomarkers and Outcomes: What's New?
Abstract Category: 35. Vascular Medicine: Non Coronary Arterial Disease
Presentation Number: 1124–161
- 2013 American College of Cardiology Foundation